TransMedics Group (NASDAQ:TMDX) PT Raised to $180.00

TransMedics Group (NASDAQ:TMDX) had its target price increased by stock analysts at Piper Sandler from $170.00 to $180.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price target suggests a potential upside of 16.64% from the stock’s current price.

Several other equities analysts have also weighed in on the stock. Morgan Stanley upped their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price on the stock. JPMorgan Chase & Co. upped their target price on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Oppenheimer upped their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Canaccord Genuity Group upped their target price on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $163.50.

TransMedics Group Stock Up 8.5 %

Shares of NASDAQ TMDX traded up $12.06 during trading on Thursday, hitting $154.32. 1,819,174 shares of the company traded hands, compared to its average volume of 748,284. The business’s fifty day moving average is $143.54 and its 200 day moving average is $110.29. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $171.98. The firm has a market capitalization of $5.08 billion, a price-to-earnings ratio of -453.88 and a beta of 1.98. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.14. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The firm had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. During the same quarter in the prior year, the business earned ($0.03) earnings per share. The business’s quarterly revenue was up 117.7% compared to the same quarter last year. Equities research analysts predict that TransMedics Group will post 0.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, Director David Weill sold 1,193 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $141.65, for a total value of $168,988.45. Following the completion of the sale, the director now directly owns 10,732 shares of the company’s stock, valued at approximately $1,520,187.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,948,714.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David Weill sold 1,193 shares of the stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $141.65, for a total transaction of $168,988.45. Following the transaction, the director now directly owns 10,732 shares of the company’s stock, valued at $1,520,187.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 113,367 shares of company stock valued at $15,145,741. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TMDX. Vanguard Group Inc. boosted its holdings in TransMedics Group by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock worth $99,341,000 after buying an additional 29,798 shares during the period. Goldman Sachs Group Inc. boosted its holdings in TransMedics Group by 10.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock worth $31,358,000 after buying an additional 38,951 shares during the period. Moody Aldrich Partners LLC boosted its holdings in TransMedics Group by 110.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company’s stock worth $3,655,000 after buying an additional 24,290 shares during the period. Alpha DNA Investment Management LLC purchased a new stake in TransMedics Group in the 4th quarter worth approximately $500,000. Finally, Russell Investments Group Ltd. lifted its stake in TransMedics Group by 337,462.5% in the 1st quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock worth $1,997,000 after purchasing an additional 26,997 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.